Donghua Zhang

This study tests a new drug combination using selinexor with reduced or no standard chemotherapy for adults with newly diagnosed AML who cannot tolerate intensive treatment. The goal is to quickly lower the number of leukemia cells in the blood while causing fewer side effects. A…

This study tests a new treatment called BCMA-GPRC5D CAR-T for people with multiple myeloma that has returned or not responded to at least three prior therapies. The goal is to see if this therapy is safe and can help control the disease. About 28 participants aged 18 to 75 will b…

This study tests a two-step treatment for people with acute myeloid leukemia (AML) that has come back or not responded to standard chemo. First, patients receive specially engineered immune cells (CLL1 CAR-T) to attack the cancer. Then, they get a stem cell transplant from a heal…

This study tests a new treatment using CAR-T cells, a type of immune cell, to fight certain blood cancers that have come back or not responded to standard therapy. The treatment targets a protein called CD7 found on cancer cells. About 20 to 28 adults aged 18-85 will take part to…

This study tests a new treatment called AcNK-Sup003 for people with a type of blood cancer (B-cell non-Hodgkin lymphoma) that has come back or not responded to other treatments. The goal is to see if it is safe and to find the best dose. About 28 adults will take part, and resear…